Meliodays and celanese partner for meliodays' development of hormone-free non-contraceptive iud designed to treat menstrual pain

Munich, july 29, 2025 (globe newswire) -- meliodays medical and celanese corporation (nyse: ce) have signed an agreement related to meliodays' pre-clinical development of melioone®, the first hormone-free non-contraceptive intrauterine device (iud) designed to deliver localized relief for menstrual pain. melioone® combines the proven vitaldose® drug delivery platform from celanese with meliodays' innovative iud design and non-hormonal active pharmaceutical ingredient (api).
CE Ratings Summary
CE Quant Ranking